Literature DB >> 16322752

PKCzeta at the crossroad of NF-kappaB and Jak1/Stat6 signaling pathways.

J Moscat1, P Rennert, M T Diaz-Meco.   

Abstract

The atypical protein kinase C (PKC) isoforms (aPKC) have been implicated in the regulation of a number of essential signaling events. Early studies using dominant-negative mutants suggested that they are important intermediaries in the activation of the canonical nuclear factor (NF)-kappaB pathway. More recent data using knockout mice genetically demonstrate that in fact the PKCzeta isoform is essential for the adequate activation of this cascade both upstream and downstream the IkappaB kinase complex. In this review, we summarize the mechanistic details whereby the aPKC pathway regulates important cellular functions and how this is achieved by the ability of these kinases to interact with different protein regulators and adapters, as well as to impinge in NF-kappaB-independent signaling cascades such as the Janus kinase-1/signal transducer and activator of transcription 6 system, which plays a critical role in T-cell-mediated hepatitis and asthma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16322752     DOI: 10.1038/sj.cdd.4401823

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  55 in total

1.  PKCzeta-regulated inflammation in the nonhematopoietic compartment is critical for obesity-induced glucose intolerance.

Authors:  Sang Jun Lee; Ji Young Kim; Ruben Nogueiras; Juan F Linares; Diego Perez-Tilve; Dae Young Jung; Hwi Jin Ko; Susanna M Hofmann; Angela Drew; Michael Leitges; Jason K Kim; Matthias H Tschöp; Maria T Diaz-Meco; Jorge Moscat
Journal:  Cell Metab       Date:  2010-07-07       Impact factor: 27.287

2.  Change in Epigenome-Wide DNA Methylation Over 9 Years and Subsequent Mortality: Results From the InCHIANTI Study.

Authors:  Ann Zenobia Moore; Dena G Hernandez; Toshiko Tanaka; Luke C Pilling; Mike A Nalls; Stefania Bandinelli; Andrew B Singleton; Luigi Ferrucci
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2015-09-09       Impact factor: 6.053

3.  Absence of neurotensin attenuates intestinal dysbiosis and inflammation by maintaining Mmp7/α-defensin axis in diet-induced obese mice.

Authors:  Jing Li; Xian Li; Jun Song; Baoxiang Yan; Stephanie A Rock; Jianhang Jia; Jinpeng Liu; Chi Wang; Todd Weiss; Heidi L Weiss; Tianyan Gao; Ashfaqul Alam; B Mark Evers
Journal:  FASEB J       Date:  2020-05-02       Impact factor: 5.191

Review 4.  Structural basis of protein kinase C isoform function.

Authors:  Susan F Steinberg
Journal:  Physiol Rev       Date:  2008-10       Impact factor: 37.312

Review 5.  Molecular basis of lysophosphatidic acid-induced NF-κB activation.

Authors:  Wenjing Sun; Jianhua Yang
Journal:  Cell Signal       Date:  2010-05-12       Impact factor: 4.315

6.  Protein kinase Czeta represses the interleukin-6 promoter and impairs tumorigenesis in vivo.

Authors:  Anita S Galvez; Angeles Duran; Juan F Linares; Peterson Pathrose; Elias A Castilla; Shadi Abu-Baker; Michael Leitges; Maria T Diaz-Meco; Jorge Moscat
Journal:  Mol Cell Biol       Date:  2008-10-27       Impact factor: 4.272

7.  Activation of keratinocyte protein kinase C zeta in psoriasis plaques.

Authors:  Yuming Zhao; Rita Fishelevich; John P Petrali; Lida Zheng; Malinina Alla Anatolievna; April Deng; Richard L Eckert; Anthony A Gaspari
Journal:  J Invest Dermatol       Date:  2008-04-03       Impact factor: 8.551

8.  γ-Tocotrienol inhibits lipopolysaccharide-induced interlukin-6 and granulocyte colony-stimulating factor by suppressing C/EBPβ and NF-κB in macrophages.

Authors:  Yun Wang; Qing Jiang
Journal:  J Nutr Biochem       Date:  2012-12-15       Impact factor: 6.048

Review 9.  TNFR1 signaling kinetics: spatiotemporal control of three phases of IKK activation by posttranslational modification.

Authors:  Lauren M Workman; Hasem Habelhah
Journal:  Cell Signal       Date:  2013-04-21       Impact factor: 4.315

10.  Ceramide signaling in cancer and stem cells.

Authors:  Erhard Bieberich
Journal:  Future Lipidol       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.